Efficacy of Oral Semaglutide in Overweight or Obesity

NCT05442450 on ClinicalTrials.gov · last registry update 2022-07-20

116 participants. Its estimated completion date, 30 June 2023, has passed with no update to the record. Primary outcome, as filed: The proportion of patients achieving a reduction in body weight of 5% or more from baseline. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Asian Institute of Gastroenterology, India
Sponsor type: Other
Enrollment: 116
Started: 2022-07-10
Primary completion: 2023-06-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The proportion of patients achieving a reduction in body weight of 5% or more from baseline

Conditions studied

Obesity · Weight Loss

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.